SCHEMBL14252707

SCHEMBL14252707

CO[C@H]1C(C(=O)O)O[C@@H](O[C@H]2C(COS(=O)(=O)O)O[C@@H](C)C(NS(=O)(=O)O)[C@H]2O)C(OS(=O)(=O)O)[C@@H]1O

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 6/20 0.70
▸ SERPINC1 P01008 3/20 0.51
▸ CXCL12 P48061 2/20 0.43
▸ CXCL10 P02778 1/20 0.43
▸ CXCL8 P10145 1/20 0.43
▸ CCL2 P13500 1/20 0.43
▸ CCL5 P13501 1/20 0.43
▸ BDNF P23560 3/20 0.42
▸ PTN P21246 2/20 0.42
▸ MDK P21741 2/20 0.42
▸ HPSE Q9Y251 3/20 0.39
▸ FGF1 P05230 3/20 0.39
▸ F2 P00734 1/20 0.39
▸ BMP2 P12643 1/20 0.38
▸ VEGFA P15692 1/20 0.38
▸ SHH Q15465 1/20 0.38
▸ FGF2 P09038 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14706300 1.00 F10 (0.70) F10SERPINC1CXCL12CXCL10CXCL8
SCHEMBL16502382 0.95 F10 (0.76) F10SERPINC1CXCL12CXCL10CXCL8
SCHEMBL23337007 0.93 F10 (0.64) F10SERPINC1CXCL12CXCL10CXCL8
SCHEMBL15199336 0.92 F10 (0.81) F10SERPINC1CXCL12CXCL10CXCL8
SCHEMBL14665995 0.92 F10 (0.81) F10SERPINC1CXCL12CXCL10CXCL8
SCHEMBL18883211 0.92 F10 (0.81) F10SERPINC1CXCL12CXCL10CXCL8
SCHEMBL10157440 0.92 F10 (0.81) F10SERPINC1CXCL12CXCL10CXCL8
SCHEMBL14960713 0.92 F10 (0.81) F10SERPINC1CXCL12CXCL10CXCL8
SCHEMBL13130300 0.90 F10 (0.84) F10SERPINC1CXCL12CXCL10CXCL8
SCHEMBL16509456 0.87 F10 (0.77) F10SERPINC1CXCL12CXCL10CXCL8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080063627-A1 Tissue graft materials containing biocompatible agent and methods of making and using same SURMODICS, INC. 2008-03-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080063627-A1 Tissue graft materials containing biocompatible agent and methods of making and using same COL1A1, COL14A1, PDGFA F10 211/4885SERPINC1 400/4885CXCL12 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback